Status:
RECRUITING
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Lead Sponsor:
Sichuan University
Conditions:
Leukemia, Lymphoid
Eligibility:
All Genders
16-65 years
Phase:
PHASE2
Brief Summary
The goal of this single-arm, prospective study is to test in low-burden B-cell lymphoblastic leukemia (B-ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main...
Eligibility Criteria
Inclusion
- patients diagnosed with B-ALL;
- patients with age ≥ 16 years;
- Availability of both pre- and post-transplantation disease status records.
Exclusion
- administration of blinatumomab therapy for more than 14 days;
- patients with leukemia burden ≥ 10% before initiation of treatment;
- patients with severe organ dysfunctions before treatment, including myocardial infarction, chronic heart failure, decompensated liver dysfunction, renal dysfunction, or gastrointestinal dysfunction;
- patients with central nervous system leukemia.
Key Trial Info
Start Date :
September 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06111625
Start Date
September 10 2023
End Date
August 31 2026
Last Update
November 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610044